Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer

Gut

Volumn 44, Issue 2, 1999, Pages 156-162

  Bennett, M W ^a   O'Connell, J ^a   O'Sullivan, G C ^b   Roche, D ^a   Brady, C ^a   Kelly, J ^a   Collins, J K ^a   Shanahan, F ^a  

^a National University of Ireland ^*  (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Apoptosis; Fas ligand; Gastric cancer; Immune escape; mRNA; Tumour

Indexed keywords

FAS LIGAND;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CELL DEATH; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; LYMPH NODE METASTASIS; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH CANCER;

EID: 0033059651     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.2.156     Document Type: Article

References (33)

1. Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995;109:1522-5.
2. Hoshino T, Seki N, Kikuchi M, et al. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 1997;70:631-8.
3. Maehara Y, Tomisaki S, Oda S, et al. Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer. Int J Cancer 1997;74:224-8.
4. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
5. Mountz JD, Zhou T, Bluethmann H, et al. Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol 1994;11:321-42.
6. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
7. Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994;152:5624-32.
8. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
9. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
10. Stuart PM, Griffith TS, Usui N, et al. CD95 ligand (FasL)- induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396-402.
11. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997;46:317-22.
12. Lau HT, Yu M, Fontana A, et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;270:109-12.
13. Arai H, Chan SY, Bishop DK, et al. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997;3:843-8.
14. O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
15. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
16. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 1996;2:1361-6.
17. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
18. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997;99:1173-8.
19. Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997;94:6420-5.
20. Bennett MW, O'Connell J, O'Sullivan GC, et al. FasL expression in oesophageal carcinoma is associated with depletion of tumor infiltrating lymphocytes. J Immunol 1998;160:5669-75.
21. Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-30.
22. Tanaka M, Suda T, Takahashi T, et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995;14:1129-35.
23. O'Connell J, Bennett MW, O'Sullivan GC, et al. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997;3:294-300.
24. Hunt JS, Vassmer D, Ferguson TA, et al. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997;158:4122-8.
25. Eischen CM, Schilling JD, Lynch DH, et al. Fc receptor-injuced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996;156:2693-9.
26. Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996;184:429-40.
27. Allison J, Georgiou HM, Strasser A, et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allograft. Proc Natl Acad Sci USA 1997;94:3943-7.
28. Kang S-M, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738-43.
29. Seino K, Kayagaki N, Okumura K, et al. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70.
30. Arai H, Gordon D, Nabel EG, et al. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997;94:13862-7.
31. Lau HT, Stoeckert CJ. FasL: too much of a good thing? Nat Med 1997;3:727-8.
32. Zhang H, Yang Y, Horton JL, et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997;100:1951-7.
33. Rayner AA, Grimm EA, Lotze MT. Lymphokine-activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985;55:1327.